RGD-targeted Au PENP / Bcl-2 siRNA polyplex
Sequence: Arg-Gly-Asp (RGD)
| Experiment Id | EXP002418 |
|---|---|
| Paper | Multifunctional PEI-entrapped gold nanoparticles enable efficient delivery of therapeutic siRNA into |
| Peptide | RGD-targeted Au PENP / Bcl-2 siRNA polyplex |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | not separately reported; vector/siRNA polyplex prepared by N/P ratio |
| Rna Concentration | 1 µg siRNA per well |
| Mixing Ratio | N/P ratio 10:1 for functional in vitro and in vivo assays |
| Formulation Format | Targeted nanoparticle/siRNA polyplex |
| Formulation Components | Bcl-2 siRNA complexed with {(Au0)25-PEI-(PEG-RGD)10-mPEG10} PENPs; PEGylated PEI, PEGylated RGD, mPEG, entrapped Au NPs. |
| Size Nm | 24.20 |
| Zeta Mv | 7.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | U87MG human glioblastoma/glioma cells overexpressing αvβ3 integrin |
| Animal Model | |
| Administration Route | |
| Output Type | Cellular uptake by flow cytometry/confocal microscopy; Bcl-2 protein knockdown by western blot |
| Output Value | Targeted Au PENP/Bcl-2 siRNA reduced Bcl-2 protein expression to 22% of control in vitro. |
| Output Units | |
| Output Notes | Cy3-siRNA uptake was confirmed by flow cytometry and confocal microscopy; RGD-targeted vector showed higher uptake than non-targeted Au PENP and produced strongest Bcl-2 knockdown. |
| Toxicity Notes | CCK-8 showed non-compromised U87MG viability even up to 3000 nM Au PENP/siRNA polyplex; RGD-targeted vector was more cytocompatible than PEI/siRNA. |
| Curation Notes |